Table 3. Multivariate analysis for OS.

Parameters	HR	95% CI	P
OS, overall survival; CLDN18.2, claudin 18 isoform 2; pos, positive; neg, negative; EGJ, gastroesophageal junction; PD-L1, programmed death-ligand 1; CPS, combined positive score; HER2, epidermal growth factor receptor 2; EBV, Epstein-Barr virus; dMMR, mismatch repair-deficient; pMMR, mismatch repair-proficient; TMB, tumor mutational burden; HR, hazard ratio; 95% CI, 95% confidence interval.
CLDN18.2 cut-off ≥2+, 40%
Age ≥60 vs. <60 (year)	0.849	0.653−1.104	0.222
Male vs. Female	0.773	0.606−0.987	0.039
CLDN18.2-pos vs. -neg	1.362	1.062−1.747	0.015
Non-EGJ vs. EGJ	0.920	0.697−1.214	0.553
Intestinal vs. Diffuse	0.719	0.535−0.968	0.030
PD-L1 CPS≥1 vs. <1	0.927	0.702−1.224	0.595
HER2-pos vs.-neg	0.737	0.504−1.076	0.114
EBV-pos vs. -neg	0.294	0.579−0.209	1.605
pMMR vs. dMMR	1.244	0.457−3.385	0.669
TMB≥10 vs. <10	1.370	0.751−2.501	0.305
CLDN18.2 cut-off ≥2+, 70%
Age ≥60 vs. <60 (year)	0.825	0.636−1.071	0.148
Male vs. Female	0.775	0.607−0.991	0.042
CLDN18.2-pos vs. -neg	1.278	1.007−1.623	0.044
Non-EGJ vs. EGJ	0.928	0.703−1.225	0.597
Intestinal vs. Diffuse	0.725	0.538−0.979	0.036
PD-L1 CPS≥1 vs.<1	0.924	0.699−1.220	0.576
HER2-pos vs. -neg	0.720	0.493−1.051	0.089
EBV-pos vs. -neg	0.579	0.208−1.607	0.294
pMMR vs. dMMR	1.206	0.443−3.287	0.714
TMB≥10 vs. <10	1.363	0.746−2.491	0.313